Centaurus Financial’s TherapeuticsMD TXMD Stock Holding History

Centaurus Financial’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-37	Closed	-$11K	–	1935
2018 Q2	$11K	Buy	+37	New	+$11.3K	﹤0.01%	1528

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Centaurus Financial's TXMD Position: Q3 2018 in Review

Centaurus Financial sold out of TherapeuticsMD (TXMD) in Q3 2018, closing a stake of 37 shares — an estimated $11K sold.

Centaurus Financial first reported a position in TXMD in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

Centaurus Financial reported no remaining TherapeuticsMD position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 37 TherapeuticsMD shares in Q3 2018, an estimated $11K.
Centaurus Financial first reported a position in TherapeuticsMD in Q2 2018 and held it in 1 quarter.
Centaurus Financial's TherapeuticsMD position peaked at $11K in Q2 2018.
155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.